⚕ GalenOps field
←

SITE001-0251

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-12-17

AEs
6
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 84); relationship: N

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-23 (study day 144); relationship: N

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-01-02 (study day 368); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-28 (study day 454); relationship: N

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-05-12 (study day 499); relationship: not assessed

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-28 (study day 546); relationship: N

Data queries

No data queries.